.jpg)
.png)
All
The word “pleiotropy” is derived from the Greek word pleon, which means “more,” and tropos, which means “way” and refers to when a gene produces two or more unrelated pleiotropic traits. The term “statin pleiotropy” has been used to refer to... more
The Foundation of the National Lipid Association (FNLA) has been hard at work in the past few months, and we have many new initiatives and accomplishments to show for it. Most recently, the FNLA helped launch an awareness campaign centered on elevated triglycerides and the role they play in a... more
A healthy lifestyle — consisting of no smoking, healthy eating, and physical activity — and adherence to prescribed risk-reducing medication are paramount to primary prevention of atherosclerotic cardiovascular disease (ASCVD). Lifestyle interventions are included as first-line therapy in all major... more
Overview Travel Grants and Awards E-Poster Submission Details FAQs Travel Grants and Awards Foundation of the NLA Donald Hunninghake Familial Hypercholesterolemia Abstract Award The Hunninghake Familial Hypercholesterolemia (FH) Award honors the highest scoring ... more
Thank you for your contribution. Your data will be viewed by our staff and posted on our website within 24 hours. <<Go back to the Career Center <<Go back to the Community <<Go back to the Photo Galleries <<Go back to the Mentoring Program
.field.field-name-field-embargo.field-type-datetime.field-label-hidden, .field.field-name-field-rating.field-type-fivestar.field-label-inline.clearfix, .links { display: none } .page-header { display: none; } .body_table li, .head_table li, .body_table p, .head_table p { line-... more
In order to bring further insight and understanding surrounding PCSK9 antibodies and their use in clinical practice, the NLA will host an in-depth supplemental symposium to be held in conjunction with the NLA 2016 Fall Clinical Lipid Update. This 2-hour symposium, held Friday, August 26 from 6... more
Key points MASLD is a risk factor for atherosclerotic cardiovascular disease and is associated with cardiometabolic risk factors, such as obesity (adiposopathy), hypertension, insulin resistance, diabetes and dyslipidemia. The cornerstone of MASLD management is aggressive treatment of risk... more
Statins reportedly are the most effective of the lipid-modifying drugs in primary and secondary prevention of coronary heart disease.1-6 Yet, many patients are deprived of the benefits of statins because of their associated complications. The most common statin-related complication is myopathy,... more
The US Food and Drug Administration recently announced changes to the safety label for the 80 milligram (mg) dose of simvastatin in the use of cholesterol lowering. The changes are the result of the FDA's review of recent clinical trials including the seven-year Study for the Effectiveness... more